NQMC Update Service: August 25, 2014 ▲ Institute for Clinical Systems Improvement

NQMC Update Service: August 25, 2014

Institute for Clinical Systems Improvement

• Lipid management in adults: percentage of patients with established ASCVD, or 10-year CHD risk greater than or equal to 10%, or diabetes and on lipid-lowering therapy who remain on lipid-lowering pharmacotherapy 12 months after therapy was prescribed.

• Lipid management in adults: percentage of patients with established ASCVD, or a 10-year CHD risk greater than or equal to 10%, or diabetes on lipid-lowering medication and most recent LDL greater than 100 mg/dL, who are prescribed a maximal recommended dose of a potent statin (such as simvastatin, pitavastatin, rosuvastatin or atorvastatin).

• Lipid management in adults: percentage of patients with established atherosclerotic cardiovascular disease (ASCVD), or 10-year CHD risk greater than or equal to 10%, or diabetes and on lipid-lowering medication who have a fasting lipid panel within 24 months of medication prescription.

• Lipid management in adults: percentage of patients with established atherosclerotic cardiovascular disease (ASCVD), or a 10-year risk for CHD greater than or equal to 10%, or diabetes, who are on a statin or have LDL less than 100 ml/dL within a 12-month period.